Q2 2023 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2023-08-11 · accession 0001104659-23-090482
$803.6M
Reported value
15
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 254604101 | IRON | Disc Medicine, Inc. | $153.7M | 19.1% | 3,461,784 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $134.7M | 16.8% | 5,858,262 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $111.2M | 13.8% | 9,885,449 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $90.8M | 11.3% | 7,608,394 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $54.9M | 6.83% | 5,836,874 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $52.5M | 6.53% | 10,907,859 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $48.7M | 6.06% | 2,098,300 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $45.5M | 5.67% | 8,279,484 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $35.0M | 4.35% | 2,039,249 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $32.9M | 4.10% | 5,018,178 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $27.7M | 3.45% | 594,251 | Common | SOLE |
| 98422T100 | — | Xilio Therapeutics, Inc. | $7.2M | 0.90% | 2,759,344 | Common | SOLE |
| 05455M100 | — | AvroBio, Inc. | $4.3M | 0.54% | 4,541,381 | Common | SOLE |
| 55910K108 | — | Magenta Therapeutics, Inc. | $2.9M | 0.36% | 3,791,698 | Common | SOLE |
| 84833T103 | SPRO | Spero Therapeutics, Inc. | $1.5M | 0.18% | 1,013,438 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.